专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11559571B2 Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine 有权
公开(公告)号：US11559571B2
公开(公告)日：2023-01-24
申请号：US16341042
申请日：2017-10-11
申请人： ISTITUTO SUPERIORE DI SANITÀ
发明人： Maurizio Paolo Maria Federico
IPC分类号： A61K39/12 , C12N15/62 , C12N15/63 , A61K39/00 , A61K9/00
摘要： The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.

2. 发明公开

US20230364211A1 NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE 审中-公开
公开(公告)号：US20230364211A1
公开(公告)日：2023-11-16
申请号：US18157534
申请日：2023-01-20
申请人： ISTITUTO SUPERIORE DI SANITÀ
发明人： Maurizio Paolo Maria FEDERICO
IPC分类号： A61K39/00 , C12N15/62 , A61K9/00
CPC分类号： A61K39/0011 , A61K39/001106 , A61K39/001186 , A61K39/00119 , C12N15/62 , A61K39/001191 , A61K9/0019 , A61K2039/572 , A61K2039/53
摘要： The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.

3. 发明授权

US11065221B2 Buthionine sulfoximine and a metallodrug for the treatment of cancer, HIV or a rheumatic disease 有权
公开(公告)号：US11065221B2
公开(公告)日：2021-07-20
申请号：US16496039
申请日：2018-03-23
申请人： ISTITUTO SUPERIORE DI SANITÀ
发明人： Iart Luca Shytaj , Shailendra Pratap Singh Rathore , Francesco Procopio , Andrea Savarino
IPC分类号： A61K31/10 , A61K33/242 , A61K31/198 , A61P35/00
摘要： There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.

4. 发明申请

US20200022937A1 BUTHIONINE SULFOXIMINE AND A METALLODRUG FOR THE TREATMENT OF CANCER, HIV OR A RHEUMATIC DISEASE 审中-公开
公开(公告)号：US20200022937A1
公开(公告)日：2020-01-23
申请号：US16496039
申请日：2018-03-23
申请人： ISTITUTO SUPERIORE DI SANITÀ
发明人： Iart Luca Shytaj , Shailendra Pratap Singh Rathore , Francesco Procopio , Andrea Savarino
IPC分类号： A61K31/198 , A61K33/242 , A61P35/00
摘要： There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.

6. 发明申请

US20210308085A1 BUTHIONINE SULFOXIMINE AND A METALLODRUG FOR THE TREATMENT OF CANCER, HIV OR A RHEUMATIC DISEASE 有权
公开(公告)号：US20210308085A1
公开(公告)日：2021-10-07
申请号：US17351350
申请日：2021-06-18
申请人： Istituto Superiore di Sanità
发明人： Iart Luca Shytaj , Shailendra Pratap Singh Rathore , Francesco Procopio , Andrea Savarino
IPC分类号： A61K31/198 , A61P35/00 , A61K33/242 , A61K33/243
摘要： There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.

7. 发明授权

US08197820B2 HIV-1 Tat, or derivatives thereof for prophylactic and therapeutic vaccination 有权
标题翻译： HIV-1 Tat或其衍生物用于预防和治疗性接种
公开(公告)号：US08197820B2
公开(公告)日：2012-06-12
申请号：US12436119
申请日：2009-05-06
申请人： Barbara Ensoli
发明人： Barbara Ensoli
IPC分类号： A61K39/21 , A61K39/12 , A61K39/38 , A61K39/00
CPC分类号： A61K39/21 , A61K38/00 , A61K39/00 , A61K39/12 , A61K2039/525 , A61K2039/53 , A61K2039/545 , A61K2039/55505 , A61K2039/55566 , C07K14/005 , C12N2710/16043 , C12N2740/16043 , C12N2740/16322 , C12N2740/16334
摘要： The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno-modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno-modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno-modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA.
摘要翻译：本发明涉及Tat作为针对HIV感染的预防和/或治疗性疫苗的活性成分，艾滋病的进展以及感染HIV的受试者的肿瘤和其他综合征和症状的发展。 Tat作为重组蛋白或肽或DNA作为生物活性形式。更具体地，本发明涉及基于作为免疫原的HIV-1 Tat的疫苗，作为DNA和/或重组蛋白或作为肽单独接种或与其它基因或病毒基因产物（Nef，Rev，Gag）或部分或与各种免疫调节细胞因子（IL-12，IL-15）组合或与编码免疫调节性细胞因子或其部分的基因组合。 Tat，Nef，Rev，Gag和免疫调节细胞因子均以重组蛋白，肽或融合蛋白（Tat / Nef，Tat / Rev，Tat / Gag，Tat / IL-12，Tat / IL- 15）或作为质粒DNA。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式